Covid19 Members

LATEST

Media Inquiries

United States

Carolyn Posner

Phone: +1 202-281-7345

Email: cposner@usibc.com


India

Priyanka Sethi

Phone: +91 9899487687

Email: psethi@usibc.com


Membership

Ryan Miller

Phone: +1 202-725-8257

Email: rmiller@usibc.com


Michael Ridings

Phone: +1 202-463-3132

Email: mridings@usibc.com


Eli Lilly

Eli Lilly and Company has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to study baricitinib as an arm in NIAID’s Adaptive COVID-19 Treatment Trial. The study will investigate the efficacy and safety of baricitinib as a potential treatment for hospitalized patients diagnosed with COVID-19, beginning this month in the U.S. with a planned expansion to additional sites including Europe and Asia. Results are expected within the next two months.